26,378 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Acquired by Inceptionr LLC

Inceptionr LLC acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 26,378 shares of the biotechnology company's stock, valued at approximately $452,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of ADMA. State Street Corp increased its holdings in shares of ADMA Biologics by 61.4% in the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company's stock valued at $259,970,000 after acquiring an additional 4,945,063 shares during the last quarter. Geode Capital Management LLC increased its stake in ADMA Biologics by 2.6% during the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company's stock valued at $107,606,000 after purchasing an additional 137,989 shares during the last quarter. Perpetual Ltd acquired a new stake in shares of ADMA Biologics during the fourth quarter worth $62,300,000. Lord Abbett & CO. LLC bought a new position in shares of ADMA Biologics in the 3rd quarter worth about $61,858,000. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of ADMA Biologics by 1,144.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock worth $51,016,000 after buying an additional 2,613,482 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th.

Remove Ads

ADMA Biologics Stock Performance

ADMA traded up $1.12 during trading on Wednesday, reaching $18.47. 3,274,347 shares of the company were exchanged, compared to its average volume of 3,325,378. ADMA Biologics, Inc. has a 52 week low of $5.88 and a 52 week high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The firm has a 50 day moving average of $16.65 and a 200 day moving average of $17.94. The stock has a market cap of $4.37 billion, a P/E ratio of 65.96 and a beta of 0.60.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.